Blood, nasopharyngeal swab and saliva

PreclinicalBiologic

Blood, nasopharyngeal swab and saliva is one of 38 biologic programs targeting Nasopharyngeal Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

21 2

Tuoyi

SSun Yat-sen University

Phase 3

11 3

Erbitux

IImclone

Phase 3

4 4

Paraplatin

AAvyxa

Phase 3

4 5

Decadron

AAspen Global Incorporated

Phase 3

1 6

Zovirax

BBp Consulting, Inc

Phase 3

1 7

Celebrex

PPhiladelphia Eye Associates

Phase 3

1 8

Gemcitabine/cisplatin

AstraZeneca

Phase 3

2 9

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

2 10

Cisplatin /m2

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2035

N/ARecruiting

Nasopharyngeal Carcinoma

NCT06870435

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

Recruiting·MMing-Yuan Chen·N/A·NCT06870435·68,649 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Blood, nasopharyngeal swab and saliva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood, nasopharyngeal swab and saliva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood, nasopharyngeal swab and saliva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ming-Yuan Chen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMing-Yuan Chen

Blood, nasopharyngeal swab and saliva

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2035

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News